源自谷歌 DeepMind 的 AI 药物发现平台 Isomorphic Labs 宣布完成 50 亿美元的 C 轮融资,旨在推动其候选药物进入临床试验阶段 1。本轮融资由 Greenoaks 和红杉资本领投,Andreessen Horowitz、GV、Capital G、Thrive Capital、MGX、Temasek 以及英国主权 AI 基金(UK Sovereign AI Fund)参与投资 1。这是创始人兼首席执行官 Demis Hassabis 卸任 DeepMind 负责人以专注于 Isomorphic Labs 药物发现业务后的首次融资 1。
Isomorphic Labs 利用基于 AlphaFold 突破成果的模拟 AI 模型进行药物设计 1。该公司此前已在肿瘤学和免疫学领域取得积极的临床前结果,并与礼来、诺华等制药巨头达成合作 1。彭博社曾报道该公司寻求以 500 亿美元估值融资,但该估值未获官方确认 1。作为参考,Isomorphic Labs 曾在 2024 年 5 月完成 21 亿美元的 B 轮融资 1。
Isomorphic Labs, an AI-driven drug discovery platform spun out of Google DeepMind, has announced a $5 billion Series C funding round aimed at transitioning its internal candidates into clinical trials. 1 The financing was led by Greenoaks and Sequoia Capital, with participation from investors including Andreessen Horowitz, GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. 1 This latest capital injection follows a $2.1 billion Series B completed in May 2024. 1
The core technology powering Isomorphic Labs is built upon the breakthrough AlphaFold protein folding model developed by DeepMind, which the startup utilizes for advanced molecular simulation and drug design. 1 Prior to this funding round, the company reported positive preclinical results specifically in the fields of oncology and immunology, while also establishing strategic partnerships with major pharmaceutical giants such as Eli Lilly and Novartis. 1 Notably, this represents the first fundraising effort since founder and CEO Demis Hassabis stepped down from his leadership role at DeepMind to dedicate himself fully to Isomorphic Labs’ mission. 1 While Bloomberg previously reported that the company sought to raise funds at a valuation of $50 billion, the final official valuation has not been confirmed in the announcement. 1
评论
还没有评论,欢迎留下第一条。